Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic small-cell lung cancer~* Metastatic high-grade neuroendocrine carcinoma of any organ system (high-grade defined by Ki-67 ≥ 20% and/or ≥ 20 mitoses/10 (HPF).~* Received at least one line of prior chemotherapy treatment for metastatic disease.~* Daily chemotherapy must be completed ≥ 2 weeks prior to registration~* Weekly chemotherapy must be completed ≥ 2 weeks prior to registration~* Chemotherapy every 2 weeks must be completed ≥ 3 weeks prior to registration~* Chemotherapy every 3 weeks must be completed ≥ 4 weeks prior to registration~* ECOG Performance Status 0 to 2~* Measurable disease by RECIST 1.1 criteria~* Age at least 18 years~* Estimated life expectancy at least 3 months~* Absolute neutrophil count ≥ 1,500/ mm³~* Platelets ≥ 100,000/mm³~* Hemoglobin ≥ 9 g/dL~* Total bilirubin ≤ 1.5 mg/dL, OR ≤ 2 X ULN if tumor involves the liver~* AST(SGOT)~* ALT(SGPT) ≤ 3 X ULN~* Creatinine ≤ 1.5 X ULN~* Creatinine clearance ≥ 45 mL/min/1.73m²) for patients with creatinine levels above institutional normal~* QT interval corrected using Fridericia's method (QTcF) \< 450 msec (males) or \< 470 msec (females)~* PR \< 240 msec~* QRS \< 100 msec~* Brain metastases must be asymptomatic and have been adequately treated with radiation finishing at least 1 week prior to initiation of study treatment.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Clinically-significant ventricular arrhythmia including cardiac arrest~* Myocardial infarction from coronary artery disease within 3 months of study enrollment~* Implantable pacemaker or implantable cardioverter defibrillator~* NYHA Class III or greater congestive heart failure~* Other clinically-significant cardiac disorders~* Family history of long QT syndrome.~* Concomitant or expected treatment with strong inhibitors of cytochrome p450 CYP2D6, specifically including Bupropion; Fluoxetine; or Paroxetine (must be discontinued at least 2 weeks or 5-half lives prior to the initiation of desipramine, whichever is shortest, except fluoxetine which requires at least a 5-week washout period).~* Use of medications known to increase risk of torsades de pointes, including Amiodarone; Arsenic trioxide; Astemizole; Azithromycin; Bepridil; Chloroquine; Chlorpromazine; Cisapride; Citalopram; Clarithromycin; Disopyramide; Dofetilide; Domperidone; Droperidol; Erythromycin; Flecainide; Halofantrine; Haloperidol; Ibutilide; Levomethadyl; Mesoridazine; Methadone; Moxifloxacin; Pentamidine; Pimozide; Probucol; Procainamide; Quinidine; Sotalol; Sparfloxacin; Terfenadine; Thioridazine; Vandetanib~* Other anti-depressant or anti-psychotic medications including selective serotonin re-uptake inhibitors (SSRIs); other tricyclic, monoamine oxidase inhibitors (MAOIs); serotonin-norepinephrine reuptake inhibitors (SNRIs, typical or atypical anti-psychotic)~* Metoclopramide (Reglan) because of increased risk of extrapyrimidal symptoms and neuroleptic malignant syndrome~* Symptomatic orthostatic hypotension despite adequate volume resuscitation.~* Medical history of narrow angle glaucoma~* Bipolar disorder, ongoing or active within the last 5 years~* Suicidal ideation, ongoing or active within the last 5 years~* Suicide attempt, ongoing or active within the last 5 years~* Pregnancy~* Breastfeeding~* Receiving any other investigational agents~* Any other serious or unstable concomitant systemic disorder that in the opinion of the investigator is incompatible with the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desipramine HCl (Type: EXPERIMENTAL): Desipramine is a tricyclic antidepressant (TCA).

Based on this trial design, predict the completion outcome and termination type (if applicable).